康拓医疗(688314) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥82,490,998.95, representing a 17.98% increase compared to ¥69,917,918.34 in the same period last year[4] - The net profit attributable to shareholders for the same period was ¥24,048,177.86, reflecting a growth of 20.63% from ¥19,935,123.47 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥23,586,583.04, which is a 25.09% increase compared to ¥18,855,036.49 in the previous year[4] - Basic and diluted earnings per share increased to ¥0.30, up 20.00% from ¥0.25 in the same period last year[4] - Net profit for Q1 2025 was ¥23,696,111.04, up 21% from ¥19,621,574.10 in Q1 2024[17] - Operating profit for Q1 2025 was ¥29,555,842.65, compared to ¥24,280,898.34 in Q1 2024, reflecting a 22% increase[17] Cash Flow - The net cash flow from operating activities decreased by 34.37%, amounting to ¥22,027,405.74, down from ¥33,563,731.94 in the previous year due to increased cash expenditures for raw materials[4][8] - Cash flow from operating activities for Q1 2025 was ¥22,027,405.74, down 34% from ¥33,563,731.94 in Q1 2024[19] - The net cash flow from financing activities was -1,117,291.26, compared to -1,003,984.71 in the previous period, indicating a decrease of approximately 11.3%[21] - Cash and cash equivalents at the end of the period totaled 293,465,001.71, down from 308,934,158.47, reflecting a decrease of about 5.5%[21] - The cash inflow from financing activities was 108,950.00, while cash outflow totaled 1,112,934.71, resulting in a significant net outflow[21] - Cash and cash equivalents as of March 31, 2025, were RMB 294,254,071.33, down from RMB 378,532,413.99 at the end of 2024, indicating a decrease of about 22.3%[12] Assets and Liabilities - Total assets at the end of the reporting period were ¥759,540,770.06, a 1.65% increase from ¥747,222,862.91 at the end of the previous year[5] - The company's total liabilities decreased from RMB 109,374,780.75 to RMB 98,157,593.42, representing a reduction of about 10.9%[14] - The total equity attributable to shareholders increased from RMB 635,577,490.21 to RMB 659,298,133.01, marking an increase of approximately 3.73%[14] - The total liabilities to equity ratio improved from approximately 0.172 to 0.149, indicating a stronger equity position relative to liabilities[14] Research and Development - Research and development expenses totaled ¥5,344,331.53, which is a 14.80% increase from ¥4,655,270.57 in the previous year, while the R&D expense ratio to operating revenue slightly decreased to 6.48%[4] - Research and development expenses for Q1 2025 were ¥4,085,868.04, slightly down from ¥4,655,270.57 in Q1 2024[17] Shareholder Information - The total number of common shareholders at the end of the reporting period was 4,435[9] - The company has not reported any significant changes in shareholder participation in margin trading or securities lending activities[11] Other Financial Metrics - The company reported non-recurring gains of ¥461,594.82, primarily from government subsidies and cash management investment income[8] - Total operating costs for Q1 2025 were ¥49,076,993.48, an increase of 10% from ¥44,390,295.19 in Q1 2024[17] - Other comprehensive income after tax for Q1 2025 was -¥161,016.57, an improvement from -¥401,085.94 in Q1 2024[18] - The impact of exchange rate changes on cash and cash equivalents was a positive 73,572.93, contrasting with a negative impact of -239,293.46 in the previous period[21] - The company paid dividends and interest totaling 465,020.73, slightly down from 468,624.40, indicating a decrease of about 0.6%[21] Accounting Standards - The company did not apply new accounting standards starting from 2025, indicating a stable accounting approach for the upcoming periods[21]